Events, By Category and Date:» Go to news main
The ethical dimensions of new human gene editing technology
Françoise Baylis presents an invited talk to the AAAS 2016 Annual Meeting. 12 February 2016 (15-16:30), Marshall Ballroom North, Marriott Wardman Park, Washington DC.
The discussion of CRISPR-Cas9 should not take place in a vacuum. It must be understood in the context of a rich history of ethical and philosophical scholarship about the relation of science to society, about the control of new technology, about various national and religious ethical traditions, and about how society has responded to a large number of other novel and powerful technologies.
- On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
- Matthew Herder Resigns from Patented Medicine Prices Review Board
- Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
- Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
- Podcast or Perish: Episode 040: Françoise Baylis
- Bioethicist Françoise Baylis asks why humans think 'they can just take everything'
- Killam Prize winners discuss research in Canada
- World‑renowned Dalhousie bioethicist and battery pioneer win prestigious Killam Prize